Wolfe Research initiates Mirum stock with outperform rating

Wolfe Research initiated Mirum Pharmaceuticals at outperform with a $145 price target versus the current $95.49 share price, while the broader consensus range sits at $129-$185. The firm highlighted multiple pipeline catalysts, including Livmarli peak sales of about $940 million, Volixibat as a potential first-approved PSC drug in 2027 with $1.7 billion worldwide peak sales, and Brelovitug/ Zilurgisertib as additional growth drivers. Q1 2026 revenue beat estimates at $159.9 million versus $148.8 million expected, although EPS missed sharply at -13.43 due to one-time acquisition costs, and the company also priced $600 million of zero-coupon convertible notes due 2032.

Analysis

MIRM is no longer just a single-product commercial story; the market is implicitly discounting a multi-asset, multi-year option set with unusually low near-term dilution risk after the recent capital raise. That matters because the convertible exchange reduces the overhang of the 2029 paper while giving management a cleaner runway to fund late-stage catalysts without resorting to equity at depressed multiples. In biotech terms, that lowers the probability of a financing-driven drawdown and shifts attention back to execution, where the stock’s sensitivity to pipeline readouts should rise.

The bigger second-order effect is competitive: if Volixibat can truly establish first-mover status in PSC, the value inflection is not just on direct sales but on the reopening of an entire orphan-GI franchise for Mirum. A credible PSC path would also pressure faster-moving adjacent developers to accelerate data disclosure or deal-making, especially any small-cap bile-acid or cholestatic players whose scarcity value is tied to being “next in line.” The market is likely underestimating how much optionality is embedded in having both an approved commercial base and a late-stage immunology/hepatology pipeline, which can support a rerating well before peak-sales math is visible in revenue.

The main risk is timing mismatch: the stock can re-rate on analyst enthusiasm now, but the fundamental proof points are spread over 12-24 months, leaving room for multiple compression if any of the 2026 readouts slip. Given the current move, the consensus may be overpaying for the pipeline while underappreciating execution risk on launch durability, payer pull-through, and the degree to which the convertible refinancing already bakes in a more favorable capital structure. On balance, this is a “show-me” setup where the upside is real, but the path depends on consecutive catalyst delivery rather than a single binary event.

For ALGS specifically, the read-through is weaker than the headline suggests: the market is rewarding the platform, not the indication, so any disappointment in one label expansion should be viewed as a sentiment shock rather than a thesis break. That makes the stock vulnerable to sharp pullbacks on delay or trial noise, but also creates a cleaner entry point if broader biotech risk appetite softens over the next few weeks.

Key Decisions for Investors

• Initiate a tactical long in MIRM on 3-6 month horizon; use pullbacks toward the post-rally moving averages as entry. Risk/reward favors upside toward the analyst consensus band if upcoming data stays on schedule, but size modestly because the catalyst stack is back-half weighted.
• Buy MIRM Jan-2027 call spreads to express the Volixibat/HDV optionality with defined downside. This is the cleanest way to capture rerating potential while limiting damage if 2026 readouts slip by a quarter or two.
• Pair trade: long MIRM / short a basket of small-cap late-stage hepatology names with no commercial revenue. The thesis is that Mirum’s balance-sheet de-risking and revenue base should outperform peers that still need external capital to survive the same catalyst window.
• If already long, harvest partial gains into strength and re-add only after any catalyst-related volatility. The stock has likely front-run some of the target-price upgrade cycle, so chasing here offers poorer reward-to-risk than buying on retracement.
• Monitor the 2026 catalyst calendar closely; if any key readout slips beyond 2Q-3Q 2026, reduce exposure. The market will likely punish delay more than it rewards distant peak-sales math.